The reference category was 25 ng/mL experienced significantly greater reductions in BMI [ = 1.02, 95% CI (1.46 to 0.58), p 25 ng/mL groups showed modest but statistically significant reductions compared to the reference group [ = 0.083, 95% CI (0.154 to 0.013), p = 0.020
We carefully regulate dosage levels to align with your personalized care plans and objectives
The clinical trials of Tirzepatide and Semaglutide show that these injections can lead to substantial weight loss, around 15-20% of body weight for the average person in the trial, and can improve type 2 diabetes, obstructive sleep apnoea, and a whole host of weight-related conditions and complications
In people with type 2 diabetes or prediabetes, GLP1 activity can also improve glucose control, which may support broader metabolic goals when paired with nutrition, activity, and medical supervision
Serious but less common risks include pancreatitis, gallbladder problems, dehydration from severe vomiting or diarrhea, worsening diabetic retinopathy in some patients with existing eye disease, and allergic reactions
.png)
